ECSP088979A - Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida - Google Patents

Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Info

Publication number
ECSP088979A
ECSP088979A EC2008008979A ECSP088979A ECSP088979A EC SP088979 A ECSP088979 A EC SP088979A EC 2008008979 A EC2008008979 A EC 2008008979A EC SP088979 A ECSP088979 A EC SP088979A EC SP088979 A ECSP088979 A EC SP088979A
Authority
EC
Ecuador
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
EC2008008979A
Other languages
English (en)
Inventor
Murat Acemoglu
Joel Slade
Joginder Singh Bajwa
Dimitris Papoutsakis
Piotr Karpinski
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088979A publication Critical patent/ECSP088979A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se preparan y se caracterizan sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida.
EC2008008979A 2006-06-12 2008-12-12 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida ECSP088979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
ECSP088979A true ECSP088979A (es) 2009-01-30

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008979A ECSP088979A (es) 2006-06-12 2008-12-12 Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida

Country Status (38)

Country Link
US (3) US20090197936A1 (es)
EP (1) EP2032531B1 (es)
JP (2) JP2009540005A (es)
KR (2) KR101629352B1 (es)
AR (1) AR061298A1 (es)
AU (1) AU2007257962B2 (es)
BR (1) BRPI0712771A2 (es)
CA (1) CA2654439C (es)
CL (1) CL2007001692A1 (es)
CR (1) CR10439A (es)
DK (1) DK2032531T3 (es)
EA (1) EA015212B1 (es)
EC (1) ECSP088979A (es)
ES (1) ES2570934T3 (es)
GE (1) GEP20105125B (es)
GT (1) GT200800279A (es)
HK (1) HK1126496A1 (es)
HN (1) HN2008001859A (es)
HR (1) HRP20160291T1 (es)
HU (1) HUE027126T2 (es)
IL (1) IL195087A (es)
JO (1) JO3138B1 (es)
MA (1) MA30563B1 (es)
ME (1) ME00531B (es)
MX (1) MX2008015901A (es)
MY (1) MY147345A (es)
NO (1) NO341871B1 (es)
NZ (1) NZ572547A (es)
PE (1) PE20080937A1 (es)
PL (1) PL2032531T3 (es)
RS (1) RS54640B1 (es)
SI (1) SI2032531T1 (es)
SM (1) SMP200900002B (es)
SV (1) SV2008003126A (es)
TN (1) TNSN08501A1 (es)
TW (1) TWI409254B (es)
UY (1) UY30403A1 (es)
WO (1) WO2007146715A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149337A (en) 2006-06-12 2013-08-30 Novartis Ag Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
AU2008204928B2 (en) * 2007-01-10 2011-03-31 Novartis Ag Formulations of deacetylase inhibitors
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
MY149337A (en) * 2006-06-12 2013-08-30 Novartis Ag Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
MA30563B1 (fr) 2009-07-01
CA2654439C (en) 2014-08-05
TNSN08501A1 (en) 2010-04-14
US20090197936A1 (en) 2009-08-06
TW200815343A (en) 2008-04-01
CR10439A (es) 2009-01-15
AU2007257962A1 (en) 2007-12-21
RS54640B1 (en) 2016-08-31
GT200800279A (es) 2010-06-16
KR20150029765A (ko) 2015-03-18
SMAP200900002A (it) 2009-01-14
GEP20105125B (en) 2010-11-25
JP2009540005A (ja) 2009-11-19
EP2032531A1 (en) 2009-03-11
NO341871B1 (no) 2018-02-12
US20100286409A1 (en) 2010-11-11
DK2032531T3 (en) 2016-04-11
IL195087A (en) 2012-10-31
US20110112308A1 (en) 2011-05-12
KR20090026281A (ko) 2009-03-12
CL2007001692A1 (es) 2008-05-09
JO3138B1 (ar) 2017-09-20
HK1126496A1 (zh) 2009-09-04
MY147345A (en) 2012-11-30
PL2032531T3 (pl) 2016-07-29
JP2013256542A (ja) 2013-12-26
JP5771257B2 (ja) 2015-08-26
ES2570934T3 (es) 2016-05-23
SMP200900002B (it) 2010-01-19
AU2007257962B2 (en) 2011-06-23
EA015212B1 (ru) 2011-06-30
TWI409254B (zh) 2013-09-21
UY30403A1 (es) 2008-01-31
SV2008003126A (es) 2011-07-05
EA200802382A1 (ru) 2009-06-30
PE20080937A1 (es) 2008-08-29
NZ572547A (en) 2011-06-30
SI2032531T1 (sl) 2016-05-31
BRPI0712771A2 (pt) 2012-09-25
HN2008001859A (es) 2011-07-19
KR101629352B1 (ko) 2016-06-13
NO20090128L (no) 2009-03-11
HUE027126T2 (en) 2016-08-29
EP2032531B1 (en) 2016-02-10
MX2008015901A (es) 2009-01-12
WO2007146715A1 (en) 2007-12-21
CA2654439A1 (en) 2007-12-21
AR061298A1 (es) 2008-08-20
IL195087A0 (en) 2009-08-03
ME00531B (me) 2011-10-10
HRP20160291T1 (hr) 2016-04-22

Similar Documents

Publication Publication Date Title
ECSP088979A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
DOP2008000068A (es) Polimorfos de n-hidroxi-3[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida